Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
A Micron five-year double thesis focused on HBM demand, DRAM/NAND cycle discipline, capital intensity, and whether AI memory improves through-cycle economics.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
A refreshed Micron Technology thesis using latest official May 2026 data, Q2 FY2026 results, HBM4 production, AI server memory demand, data-center mix, U.S. manufacturing updates, capex, balance-sheet strength, and cycle risk.
OpenAEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
OpenAmerican Integrity is a newly public but seasoned Florida residential property insurer. The latest filings show 437,308 policies in force, $974.8 million of in-force premium, a 75.0% Q1 combined ratio and a reduced non-catastrophe quota share that lets AII kee
OpenAIG is now a focused global P&C underwriting and capital-return story. The latest filings show a 90.1 General Insurance combined ratio in 2025, an 87.3 combined ratio in Q1 2026, heavy buybacks, a smaller Corebridge stake and a live CEO transition.
OpenAssured Guaranty is a financial guaranty insurer with Q1 2026 new-business growth, record adjusted book value per share and a long buyback record, but the equity case still depends on ratings strength, insured-credit losses, PREPA and disciplined capital alloc
OpenAflac is a high-return supplemental insurer with a real capital-return engine, but its quality case still depends on Japan premium trends, yen translation, regulatory capital and investment marks.
OpenAmerican Financial Group's Q1 2026 specialty P&C engine produced a 90.3% combined ratio and $206 million of core net operating earnings, but the thesis still depends on reserve quality, catastrophe control and disciplined capital returns.
OpenAdaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenADCT already sells ZYNLONTA, but the story is not solved by having revenue. The next question is whether the 2026 lymphoma data can widen the drug's role before cash burn, royalties, debt, and dilution take the lead.
OpenEnact is profitable, overcapitalized against PMIERs, and returning cash through dividends and buybacks, but the public-company thesis still runs through mortgage credit, GSE rules, housing affordability, reinsurance markets, and Genworth's 81% control.
OpenAdagene is trying to turn SAFEbody antibody masking into a broader immuno-oncology platform. The hook is muzastotug's early dose-dependent signal; the catch is that randomized proof, partner execution, and financing still decide the stock.
OpenActuate has a company-defining elraglusib Phase 2 pancreatic-cancer survival signal and a new oral IND, but the same source set shows no product revenue, going-concern disclosure, and a need for capital beyond July 2026.
OpenAmerican Coastal is a concentrated Florida commercial property insurer with excellent recent combined ratios, fast book-value growth, and a fresh catastrophe-bond layer. The hard part is that nearly every attractive metric depends on hurricane losses, reinsura
OpenArch is not hard to like after an 81.7% combined ratio, $1.0 billion of Q1 net income, and $783 million of buybacks. The harder question is whether reserves, catastrophe losses, mortgage credit, and reinsurance pricing stay friendly enough for that capital mac
OpenOfficial-source baseline for Ascentage Pharma using SEC submissions, FY2025 Form 20-F, SEC companyfacts, company-filed FY2025 results releases, ASCO 2026 update, annual meeting materials, and oncology peer filings.
OpenOfficial-source baseline for Atlantic American using SEC submissions, SEC XBRL companyfacts, the FY2024 10-K, Q3 FY2025 10-Q, 2025 earnings 8-K, FY2025 NT 10-K, Nasdaq notice 8-K, CFO resignation 8-K, proxy, and peer SEC filings.
OpenTag facets appear after tag usage counts are rebuilt.